ChemoTech’s Animal Care Enters Strategic Collaboration with Norwegian Veterinary University’s Hospital for Equine Medicine
Scandinavian ChemoTech AB’s subsidiary dedicated to Animal Care has entered a clinical partnership with the Norwegian University of Life Sciences (NMBU) Hospital for Equine Medicine. Following an extensive evaluation period, NMBU’s Equine team, led by Professor and DVM Cathrine Fjordbakk, has decided to integrate ChemoTech’s Tumour-Specific Electroporation (TSE) therapy into their routine treatment offerings. This partnership aims to set new standards in veterinary oncology and reach new scientific milestones.
This collaboration and commercial agreement not only strengthen the clinical adoption of TSE therapy in equine medicine but also marks an important academic partnership between Vetiqure AB and NMBU. Together, we will work to explore and expand therapeutic options in veterinary oncology, while advancing research and innovation around the TSE platform.
“We are thrilled to attract the attention of such a respected academic institution as NMBU,” said Mohan Frick, CEO and Co-Founder of Scandinavian ChemoTech.
“This collaboration presents an exciting opportunity to push forward our research and development initiatives. With NMBU as a partner, we can build momentum toward establishing TSE therapy as a new standard in animal cancer care.”
Professor Fjordbakk highlighted the value of this collaboration for the veterinary field:
“It is encouraging to see more companies committed to advancing treatment options for veterinarians. TSE’s minimally invasive approach aligns well with our clinical needs, as this new treatment often allows us to treat horses without requiring general anaesthesia. This is a significant advantage in equine care.”
This strategic partnership with NMBU exemplifies ChemoTech’s commitment to enhancing the standards of animal care through pioneering technology and underscores its dedication to creating safer, more precise, dynamic and effective cancer therapies for animals.
For further information please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se
Certified Adviser: Redeye AB
This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 05-11-2024 09:20 CET.
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.
